Daniel is a partner in Kirkland's IP litigation team in London. Daniel's practice is focused on life science patent litigation, particularly in the pharmaceutical industry, diagnostics and the emerging fields of precision medicine and cell and gene therapy.

In addition to UK based litigation, Daniel assists his clients with the strategic coordination and alignment of complex patent strategy to address loss-of-exclusivity events at a pan-European and global level. With dual qualifications in law and biochemistry, and experience litigating in both Australia and Europe, Daniel is readily able to grasp highly technical material and the international dimensions of multijurisdictional disputes which are often central to the development of strategy for blockbuster litigation on behalf of the most sophisticated clients.

A strong believer in the power of scientific innovation in healthcare and medicine to improve clinical outcomes and quality of life, and the role of intellectual property in incentivising and protecting such innovation, Daniel often represents leading life science companies for whom such innovation is core to their business.

Daniel has developed a particular interest and experience in the rising gene editing technology CRISPR, and is recognised as a thought leader and regular writer, speaker and commentator on the topic. Daniel's previous case experience covers a broad range of technical fields within life sciences, including oncology, immunology, neurology, molecular diagnostics, formulation science, pharmacokinetics, clinical pharmacology and biostatistics.

Daniel has been recognised as a Rising Star in IP by Managing Intellectual Property in both 2017 and 2018. He was further recognised as a Rising Star in Life Sciences by Expert Guides in 2019. Daniel has also spent time on secondment in-house to the generic arm of a leading global pharmaceutical company, and spent a year as Associate to Justice Yates of the Federal Court of Australia. Prior to joining Kirkland, Daniel was a lawyer at Australian top tier firm Clayton Utz, and senior associate at magic circle firm Allen & Overy.


Thought Leadership


“Crunch Time (Part 1),” Intellectual Property Magazine, 28 February 2020

“Patent Litigation 2020: Trends and Developments,” Chambers and Partners Practice Guides, 10 February 2020

“CRISPR picture (Part 1),” Intellectual Property Magazine, 24 January 2020

Co-author of UK chapter in “Antibody Patenting: A Practitioner's Guide to Drafting, Prosecution and Enforcement”, AIPPI Law Series published by Wolters Kluwer, 2019

The future of precision medicine part 7: public engagement”, Life Sciences Intellectual Property Review, 29 August 2019

The future of precision medicine part 6: reimbursement”, Life Sciences Intellectual Property Review, 8 August 2019

The future of precision medicine part 5: keeping pace with regulation”, Life Sciences Intellectual Property Review, 26 July 2019

“How to empower young IP lawyers to be leaders”, Managing Intellectual Property, 24 July 2019

“Patent Litigation 2019: Trends and Developments”, Chambers and Partners Practice Guides, 20 June 2019

Academia in the City: Bridging the gap between legal theory and practice”, Per Incuriam, 15 February 2019

The future of precision medicine part 4: diagnosing the diagnostic problem”, Life Sciences Intellectual Property Review, 14 February 2019

“Moving towards a cure in genetics: what is needed to bring somatic gene therapy to the clinic?”, European Journal of Human Genetics, 19 December 2018

Patents, platform technologies and new therapeutic modalities”, IAM, 30 November 2018

Four patent lessons the tech sector can teach life sciences companies”, IAM, 2 November 2018

The four big trends that will transform life sciences patent strategies”, IAM, 1 November 2018

The future of precision medicine part 3: translation from research to the clinic”, Life Sciences Intellectual Property Review, 23 October 2018

The future of precision medicine part 2: data is king”, Life Sciences Intellectual Property Review, 17 July 2018

The future of precision medicine part 1: challenges and opportunities”, Life Sciences Intellectual Property Review, 13 June 2018

“Disruption and development: the evolving CRISPR patent and technology landscape”, Pharmaceutical Patent Analyst, 8 June 2018

“More than Just a Game (Report 3): Loot boxes and gambling”, IP Kat, 22 February 2018

“More than Just a Game (Report 2): Music, video games, GDPR & technical protective measures”, IP Kat, 22 February 2018

“More than Just a Game (Report 1): eSports”, IP Kat, 17 February 2018

“Patent suits mount up but CRISPR industry rolls on regardless”, Intellectual Property Magazine, 26 January 2018

“CRISPR Update part 1 – Crowded field”, Intellectual Property Magazine, 5 December 2017

“Questions about CRISPR”, Intellectual Property Magazine, 29 March 2017

“AIPPI Congress Report 5: Antitrust and Pharma - seeking a balance”, IP Kat, 29 November 2016

“AIPPI Congress Report 2: AIPPI for the uninitiated – day 1 as a conference ingénue”, IP Kat, 18 September 2016


Moderator, “Brexit and IP: an update”, AIPPI World Congress – London, 17 September 2019

Moderator, “Patent litigation strategies in advance of the launch of new biologic medicine”, Managing IP International Patent Forum panel, 6 March 2019

“Somatic gene editing: Legal and regulatory aspects – what is needed to launch genome editing in the clinic?”, European Society of Human Genetics, 18 June 2018

“CRISPR’s IP licensing landscape”, Intellectual Property Magazine Webinar, 5 December 2017

“CRISPR: Legal and regulatory considerations”, CRISPRcon table talk, 16 August 2017

Press Coverage

Quoted “Breaking: EPO revokes Broad’s CRISPR patent,” Life Sciences Intellectual Property Review.16 January 2020

Quoted “Broad Institute facing tough fight in CRISPR patent appeal hearing,” IAM, 14 January 2020 

Quoted “Should I stay or should I go? Private practice v in-house”, Managing Intellectual Property, 18 September 2019

Quoted “Beware the pay gap: Lawyers who shun an in-house switch”, Managing Intellectual Property, 21 August 2019

Quoted “Precision medicine: The personal touch”, Life Sciences Intellectual Property Review, 21 May 2019

Quoted “UCal granted wide-ranging CRISPR rights, but future patent landscape remains uncertain”, IAM, 30 April 2019

Quoted, “The big life sciences patent news from February”, IAM, 11 March 2018

Quoted, “Locus licenses CRISPR tech to Janssen in potential $818m deal”, Life Sciences Intellectual Property Review, 9 January 2019

Quoted, “Top 10 patent cases of the year”, JUVE Patent, 21 December 2018

Quoted, "Revolutionary change in CRISPR patent landscape poses tough questions for life sciences companies", IAM, 27 July 2018

Quoted, "EPO revokes Broad’s CRISPR patent", Nature Biotechnology, 6 March 2018

Quoted, "European Patent Office revokes Broad Institute CRISPR patent", BioWorld, 19 January 2018

Quoted, "CRISPR opposition hearing kicks off at European Patent Office", AgroNews, 19 January 2018


World IP Review — WIPR Leaders, 2020 

Euromoney Legal Media Group Europe Rising Stars Awards 2019 — Winner — Rising Star: Life Sciences; Rising Star: UK

Expert Guides 2019 — Rising Star: Life Sciences, UK

Managing Intellectual Property IP STARS — Rising Star, 2017–2018

Memberships & Affiliations

International Association for the Protection of Intellectual Property (AIPPI)

  • Vice-Chair of Standing Committee on Biotechnology
  • Member of Standing Committee on IP and genetic resources/traditional knowledge
  • Member of the UK Group

EPLAW – European Patent Lawyers Association


Admissions & Qualifications

  • 2012Supreme Court of New South Wales
  • 2012High Court of Australia


  • University of OxfordPostgraduate Diploma in Intellectual Property Law and PracticeDistinction2016
  • The University of SydneyLL.B.First Class Honours2011

    University of Sydney Law Revue

    Minter Ellison Prize for Intellectual Property, 2010

  • The University of SydneyB.Sc.First Class Honours2009